IGM Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- IGM Biosciences's estimated annual revenue is currently $32.5M per year.
- IGM Biosciences's estimated revenue per employee is $118,364
- IGM Biosciences's total funding is $592M.
- IGM Biosciences's current valuation is $710.3M. (January 2022)
Employee Data
- IGM Biosciences has 275 Employees.
- IGM Biosciences grew their employee count by 25% last year.
IGM Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.1M | 46 | 24% | N/A | N/A |
What Is IGM Biosciences?
IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM and IgA antibodies that improve the treatment of cancer and other diseases since 2010. IGM is working to develop IgM and IgA antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com
keywords:N/A
$592M
Total Funding
275
Number of Employees
$32.5M
Revenue (est)
25%
Employee Growth %
$710.3M
Valuation
N/A
Accelerator
IGM Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Business Officer | |
2 | Senior Director Clinical Development | |
3 | VP Government Affairs | |
4 | Scientist I | |
5 | Associate Director Clinical Operations | |
6 | Director Environment Health Safety | |
7 | Senior Clinical Trial Manager | |
8 | Associate Director | |
9 | Senior Research Associate | |
10 | Director |
IGM Biosciences News
IGM Biosciences didn't skip a beat capitalizing on all the new love pouring in for its stock. Just hours after unveiling a deal with Sanofi worth up to...
IGM Biosciences is developing IgM antibodies that could have serious advantages over the antibodies used in many of today's top-selling biologic...
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing...
Chris Takimoto Chris Takimoto, the former CMO at Forty Seven who completed a stint as SVP of oncology R&D at Gilead after the buyout, is moving on. He’s been given the CMO spot at IGM Biosciences. Takimoto is taking the place of Dan Chen, a former top oncology researche ...
IGM Biosciences picked up $102 million in series C financing to work on its pipeline of cancer drugs, including a CD20- and CD3-targeting bispecific antibody slated to start clinical trials by the end of the year. Sponsored by Agilent Technologies How would you like to win free bench space at ...
Other Companies in Mountain View
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $60.5M | 276 | 3% | $164M |
#2 | $39.3M | 279 | 31% | $84.7M |
#3 | $43.6M | 280 | 4% | $105.8M |
#4 | $43.1M | 280 | 31% | N/A |
#5 | $60.7M | 284 | 16% | $45.3M |